1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea_product_DataBase

Bioactivity	STAT3-IN-7 is a Sorafenib analogue and potently inhibits the phosphorylation of STAT3. STAT3-IN-7 induces cell apoptosis through SHP-1 dependent STAT3 inactivation. STAT3-IN-7 does not inhibit kinase activity and has anticancer effects[1].
Invitro	STAT3-IN-7 (SC-1; 1-10 μM; 48 hours; breast cancer cells) treatment demonstrates dose-dependent suppression of cell viability in all tested breast cancer cells[1].STAT3-IN-7 (SC-1; 1-10 μM; 36 hours; breast cancer cells) treatment induces potent apoptotic activity[1].STAT3-IN-7 (SC-1; 1-10 μM; 36 hours; breast cancer cells) treatment shows downregulation of p-STAT3 and its downstream proteins cyclin D1 and survivin in a dose-dependent manner in breast cancer cell lines[1]. Cell Viability Assay[1] Cell Line:
In Vivo	STAT3-IN-7 (10 mg/kg; oral gavage; daily; for 28 days; female NCr athymic nude mice) treatment shows efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors[1]. Animal Model:
Name	1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea
CAS	1313019-65-6
Formula	C21H13ClF3N3O2
Molar Mass	431.80
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Chun-Yu Liu, et al. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Res. 2013;15(4):R63.

PeptideDB